SOTRET
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOTRET (SOTRET).
Binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription to reduce sebum production, normalize follicular keratinization, and inhibit Propionibacterium acnes growth.
| Metabolism | Primarily hepatic via CYP450 isoenzymes (CYP2B6, CYP2C8, CYP3A4) to active metabolites: 4-oxo-isotretinoin, tretinoin, and 4-oxo-tretinoin. |
| Excretion | Primarily hepatic metabolism with renal excretion of metabolites (approximately 60-80% in urine) and fecal elimination (15-30%). |
| Half-life | Terminal elimination half-life: 18-20 hours in adults; steady-state achieved after 5-7 days of dosing. |
| Protein binding | 99.9% bound to albumin, primarily to albumin. |
| Volume of Distribution | Approximately 2.5-5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: Approximately 25% due to extensive first-pass metabolism; absorption significantly increased (up to 2-fold) when taken with a high-fat meal. |
| Onset of Action | Oral: Clinical improvement in acne vulgaris typically observed within 4-8 weeks. |
| Duration of Action | Duration of therapeutic effect continues for weeks to months after discontinuation; remission may persist for prolonged periods. |
| Molecular Weight | 300.44 |
| Action Class | Retinoids- First generation |
| Brand Substitutes | Isac 20mg Capsule, Reznin 20mg Capsule, Popout 20mg Capsule, Tretiva 20 Capsule, Systroin 20 Capsule, Trato 10mg Soft Gelatin Capsule, Isoden 10mg Soft Gelatin Capsule, Adclin 10mg Soft Gelatin Capsule, Aknea 10 Softgel Capsule, Mavtron 10mg Soft Gelatin Capsule, Saferet 30mg Capsule, Nidtroin 30mg Capsule, Isofree 30mg Capsule, Acutret 30 Capsule, Isotroin 0.05% Gel, Acno Gel, Isofeel 40 Softgel Capsule, Tretiva 40 Capsule, Nutret 5mg Capsule, Isotino 5mg Capsule, Isokon 5mg Capsule, Isotane 5mg Capsule, Retizo 5mg Capsule |
Oral isotretinoin 0.5-1 mg/kg/day divided twice daily for 15-20 weeks.
| Dosage form | CAPSULE |
| Renal impairment | Contraindicated in severe renal impairment (CrCl <30 mL/min). For CrCl 30-59 mL/min, reduce dose by 50%. No adjustment for CrCl ≥60 mL/min. |
| Liver impairment | Contraindicated in Child-Pugh class B or C. For Child-Pugh class A, reduce dose by 50% and monitor LFTs. |
| Pediatric use | For children ≥12 years: 0.5-1 mg/kg/day (max 2 mg/kg/day) divided twice daily for 15-20 weeks. For <12 years, safety not established. |
| Geriatric use | No specific dose adjustment; use lowest effective dose (0.5 mg/kg/day) due to increased risk of adverse effects (e.g., hypertriglyceridemia, musculoskeletal pain). |
| 1st trimester | Contraindicated: isotretinoin is a known teratogen causing severe fetal malformations including CNS abnormalities, facial dysmorphism, and cardiovascular defects. Pregnancy must be excluded before initiation. |
| 2nd trimester | Contraindicated: continued risk of teratogenicity throughout second trimester. Use only if patient has confirmed negative pregnancy test and is using effective contraception. |
| 3rd trimester | Contraindicated: risk of premature closure of epiphyses and other adverse effects. Avoid use in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for SOTRET (SOTRET).
| Placental transfer | Isotretinoin crosses the placenta extensively. Animal studies show placental transfer with fetal tissue distribution. Human data demonstrate embryotoxicity and teratogenicity at therapeutic doses. |
| Breastfeeding | Isotretinoin is excreted in human milk at low concentrations. Due to potential adverse effects on the infant, including possible carcinogenicity and skin/mucous membrane reactions, breastfeeding is not recommended during therapy and for at least 8 days after the last dose. |
■ FDA Black Box Warning
Isotretinoin is contraindicated in women of childbearing potential unless they meet strict conditions for pregnancy prevention due to its teratogenicity. It is also associated with increased risk of suicidal thoughts and behaviors, pseudotumor cerebri, and severe skin reactions.
| Serious Effects |
Pregnancy or suspected pregnancyWomen of childbearing potential not using two forms of effective contraceptionHypersensitivity to isotretinoin or any component of the formulationConcomitant use with tetracyclines (risk of pseudotumor cerebri)Concomitant use with vitamin A supplements (risk of hypervitaminosis A)Breastfeeding
| Precautions | Teratogenicity: Absolute contraindication in pregnancy; must ensure negative pregnancy test and use two forms of contraception., Psychiatric disorders: May cause depression, psychosis, suicidal ideation; monitor mental health., Pseudotumor cerebri: Risk increases with concomitant tetracyclines., Hypertriglyceridemia: Monitor lipids; may lead to pancreatitis., Hepatotoxicity: Monitor liver enzymes; avoid alcohol., Skeletal hyperostosis: Long-term use may cause premature epiphyseal closure., Nocturnal vision loss: Rare; caution with night driving., Inflammatory bowel disease: Rare reports; discontinue if symptoms occur. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | SOTRET (isotretinoin) is a known human teratogen. Exposure during pregnancy, particularly between weeks 3 and 6 of gestation, is associated with a high risk of major congenital malformations including craniofacial defects (micrognathia, cleft palate), cardiovascular abnormalities, central nervous system anomalies (hydrocephalus, microcephaly), thymic and parathyroid gland abnormalities. Therefore, isotretinoin is contraindicated in pregnant women or those of childbearing potential unless they meet strict conditions of pregnancy prevention. |
| Fetal Monitoring | Prior to initiation, confirm negative pregnancy test. Monthly in-treatment pregnancy tests are mandatory. Liver function tests, lipid panel, and renal function should be monitored at baseline and monthly due to potential hepatotoxicity, hyperlipidemia, and renal effects. Patients should be monitored for signs of pseudotumor cerebri (headache, visual disturbances). |
| Fertility Effects | Isotretinoin may transiently affect spermatogenesis in males, but data do not indicate permanent sterility. In females, isotretinoin does not impair fertility; however, due to teratogenicity, effective contraception is mandatory during therapy and for 1 month after discontinuation. |
| Food/Dietary |
| Take SOTRET with a full meal containing at least 20 grams of fat to enhance absorption. Grapefruit juice may increase isotretinoin levels; avoid concurrent intake. Alcohol consumption is strongly discouraged due to additive hepatotoxic effects. No other significant food interactions reported. |
| Clinical Pearls | SOTRET (isotretinoin) is a retinoid indicated for severe recalcitrant nodular acne. It requires strict pregnancy prevention due to teratogenicity; two forms of contraception are mandatory for females of childbearing potential. Monitor for mood changes, suicidal ideation, and pseudotumor cerebri (headache, visual disturbances). Baseline and monthly liver function tests, fasting lipid panel, and pregnancy tests are essential. Avoid concurrent tetracyclines due to increased risk of pseudotumor cerebri. Dryness of skin and mucous membranes is expected; use emollients and artificial tears. |
| Patient Advice | Do not become pregnant or father a child while taking SOTRET; use two forms of effective birth control. · Take SOTRET with food, preferably with a fatty meal, to increase absorption. · Do not donate blood during therapy and for one month after discontinuation. · Report severe headache, vision changes, mood swings, or suicidal thoughts immediately. · Avoid waxing, dermabrasion, or laser treatments while on SOTRET and for 6 months after. · Expect dry lips, skin, and eyes; use moisturizers and lip balm liberally. · Avoid alcohol consumption due to potential liver toxicity. · Keep out of direct sunlight and use broad-spectrum sunscreen SPF 30+ daily. |